Leslie Caromile
Has grant
Assistant Professor
Research Interests
Make your next move.
Prepare your application
Review drafts before you send them.
Explore related searches
About
Dr. Leslie Caromile is an Assistant Professor at the University of Connecticut School of Medicine, USA. Her research areas include genetic determinants of cellular functions, diversity in biomedical sciences recruitment, therapeutic strategies for cancer treatment, and the impact of systemic racism in higher education. Dr. Caromile's recent publications reflect her commitment to advancing knowledge in these critical fields.
Recent Grants
Grant: Close
Frontiers in Bone Metastatic Models for Prostate Cancer
Open Date: 2024-07-01
Close Date: 2026-06-30
Grant: Close
Increasing Research Experiences for Multicultural Students
Open Date: 2022-02-01
Close Date: 2025-01-31
Grant: Close
Near-IR Ratiometric Fluorescence Probes for Assessing Cargo Delivery to Prostate Tumors
Open Date: 2021-01-14
Close Date: 2024-12-31
Grant: Close
Prostate-Specific Membrane Antigen-Dependent Health Disparities in Prostate Cancer
Open Date: 2020-09-30
Close Date: 2025-09-29
Grant: Close
PSMAs role in signal transduction pathway switching in prostate cancer
Open Date: 2014-08-07
Close Date: 2019-07-31
Articles (7)
Academics are familiar with the concept of a growth mindset, a framework teachers use to help students embrace challenges, overcome obstacles, and learn from their mistakes. In this context, we argue that the principles of this paradigm are equally applicable in promoting the career advancement of early STEM academics, as well as those in non-STEM fields where successful career progression requires demonstrating contributions to scholarship, teaching, and service, often involving collaborative work. The early years of a faculty career offer numerous opportunities for growth, but these may be missed or seen as obstacles if approached with a fixed mindset. This is especially true for individuals with intersectional identities who may lack role models or feel out of place in an unsupportive academic environment. We argue that a well-planned, purposeful, and balanced approach to workload responsibilities that aligns with institutional culture and priorities can lead to outstanding performance and career advancement, enabling individuals to achieve their aspirations and personal goals.
Year:
2025
Start-up packages were once predominantly associated with research-intensive institutions. However, they are now increasingly important for teaching-focused and primarily undergraduate institutions due to rising expectations for research involvement. Effective negotiation for tenure-track start-up packages is essential for aligning the candidates' and institutions' interests and goals. Candidates must understand the various components of an offer, such as start-up funds, teaching loads, research expectations, and tenure requirements, to negotiate terms that align with their needs and goals. However, navigating these negotiations can be daunting, particularly for individuals from historically underserved and excluded groups (HUE) in STEM fields who may lack access to supportive networks. In this article, we aim to provide a detailed guide on how to negotiate an effective tenure-track start-up package. We emphasize that this process can be beneficial for both the candidate and the institution, as it helps ensure that their values and goals are aligned, ultimately increasing the chances of success for both parties. This article builds upon our earlier publications and provides comprehensive guidance for negotiating strategies.
Year:
2025
Zinc (Zn) is a vital micronutrient with essential roles in biological processes like enzyme function, gene expression, and cell signaling. Disruptions in the cellular regulation of Zn2+ ions often lead to pathological states. Mammalian Zn transporters, such as ZIP11, play a key role in homeostasis of this ion. ZIP11 resides predominately in the nucleus and Golgi apparatus. Our laboratory reported a function of ZIP11 in maintaining nuclear Zn levels in HeLa cervical cancer cells. Analyses of cervical and ovarian cancer patients’ datasets identified four coding, single nucleotide polymorphisms (SNPs) in SLC39A11, the gene that encodes ZIP11, correlating with disease severity. We hypothesized that these SNPs might translate to functional changes in the ZIP11 protein by modifying access to substrate availability. We also proposed that a metal-binding site (MBS) in ZIP11 is crucial for transmembrane Zn2+ transport and required for maintenance of various pathogenic phenotypes observed in HeLa cells. Here, we investigated these claims by re-introducing single the SLC39A11 gene encoding for mutant residues associated with the SNPs, as well as MBS mutations into HeLa cells knocked down for the transporter. Some SNPs-encoding ZIP11 variants rescued Zn levels, proliferation, migration, and invasiveness of knockdown (KD) cells. Conversely, single MBS mutations mimicked the traits of KD cells, confirming the transporter's role in establishing and maintaining proliferative, migratory, and invasive traits. Overall, the intricate role of Zn in cellular dynamics and cancer progression underscores the significance of Zn transporters like ZIP11 in potential therapeutic interventions.
Year:
2024
Transgender females undergoing hormone replacement therapy (HRT) as a component of the gender affirmation treatment (GAT) commonly retain their prostate, rendering them susceptible to developing prostate cancer (PC). Currently, patients with localized PC receive endocrine therapy ( e.g., androgen ablation/castration). Once metastatic, patients undergo standard chemotherapy and/or novel treatment. Unfortunately, many fail to respond completely and develop untreatable, drug-resistant tumors consistent with reprogramming of crucial cell signal transduction pathways that promote tumor growth, invasiveness, and survival. There is no consensus among scientists or physicians on how HRT affects PC treatment options or its related signaling pathways, putting patients at risk for delayed diagnosis. This scoping review aims to analyze and collate the current scientific literature on PC progression in transgender females who have undergone HRT and how PC-initiated oncogenic pathways are impacted by HRT. The review’s findings can potentially inform transgender healthcare and research. This scoping review will follow the Population-Concept-Context methodology for Joanna Briggs Institution Scoping Reviews. Relevant peer-reviewed studies will be identified from the following electronic databases: MEDLINE (PubMed), Embase (Elsevier), CINAHL (EBSCO), and Scopus (Elsevier). Sources of unpublished studies/ grey literature to be searched include bioRxiv (Cold Spring Harbor Laboratory), medRxiv (Cold Spring Harbor Laboratory), and MedNar (Deep Web Technologies). The search strings using keywords such as gender-affirmation treatment, transgender females, and prostate cancer will be conducted using Boolean logic. There will be no limitation on language or date of publication.
Year:
2024
Year:
2023
Year:
2022
Year:
2020
Collaborators (1)
Jim Vigoreaux
Professor
University of Vermont
Make your next move.
Prepare your application
Review drafts before you send them.